TNYA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TNYA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Tenaya Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-31.45 Mil. Tenaya Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Tenaya Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Tenaya Therapeutics's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Tenaya Therapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Tenaya Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Interest Coverage | No Debt | No Debt | N/A | N/A | N/A |
Tenaya Therapeutics Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Interest Coverage | Get a 7-Day Free Trial | N/A | N/A | N/A | N/A | N/A |
For the Biotechnology subindustry, Tenaya Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Tenaya Therapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Tenaya Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as
Here, for the fiscal year that ended in Dec. 2023, Tenaya Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-131.19 Mil. And its Long-Term Debt & Capital Lease Obligation was $8.11 Mil.
GuruFocus does not calculate Tenaya Therapeutics's interest coverage with the available data. |
Tenaya Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
Here, for the three months ended in Dec. 2023, Tenaya Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-31.45 Mil. And its Long-Term Debt & Capital Lease Obligation was $8.11 Mil.
GuruFocus does not calculate Tenaya Therapeutics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Tenaya Therapeutics (NAS:TNYA) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Tenaya Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy Hoey | officer: Chief Scientific Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080 |
Leone D Patterson | officer: Chief Fin and Bus. Officer | |
Whittemore Tingley | officer: Chief Medical Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Faraz Ali | director, officer: Chief Executive Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080 |
David V Goeddel | director, 10 percent owner | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Iii Gp, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Amy L. Burroughs | director | TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Column Group Iii, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Opportunity Iii Gp, Lp | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Tcg Opportunity Iii Gp, Llc | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Column Group Opportunity Iii, Lp | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Deepak Srivastava | director | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Column Group Iii-a, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Eli Casdin | director | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Casdin Capital, Llc | director | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
From GuruFocus
By Marketwired • 10-02-2023
By Marketwired • 08-31-2023
By Stock market mentor Stock market mentor • 02-07-2023
By Business Wire Business Wire • 05-03-2022
By Stock market mentor Stock market mentor • 01-09-2023
By Value_Insider Value_Insider • 11-21-2022
By sperokesalga sperokesalga • 04-21-2023
By PurpleRose PurpleRose • 08-10-2022
By Business Wire Business Wire • 06-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.